• Biz Industry

SUPRIYA LIFESCIENCE LIMITED INITIAL PUBLIC OFFERING TO OPEN UP ON DECEMBER 16, 2021


SUPRIYA LIFESCIENCE LIMITED INITIAL PUBLIC OFFERING TO OPEN UP ON DECEMBER 16, 2021

· Price Band fixed at Rs 265 to Rs 274 per equity share of face value of Rs. 2 each of Supriya Lifescience Limited (“Equity Shares”)


· Bid /Offer Opening Date – Thursday, December 16, 2021 and Bid/ Offer Closing Date – Monday December 20, 2021

Mumbai, December 13, 2021: Supriya Lifescience Limited (The “Company”) to open its Bid / Offer in relation to its initial public offering on December 16, 2021.


The Price Band of the offer has been fixed at Rs. 265 to Rs. 274 per Equity Share. Bids can be made for a minimum of 54 Equity Shares and in multiples of 54 equity shares thereafter.

The company plans to raise funds aggregating upto Rs. 7000 million. The offer comprises of fresh issue of equity shares aggregating upto Rs. 2000 million by the Company (The “Fresh Issue”) and offer for sale aggregating upto Rs. 5000 million by Mr Satish Waman Wagh (The “Promoter Selling Shareholder”), (The "Offer for Sale”, together with the Fresh Issue, the “Offer”.)


This Offer is being made in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended (“SCRR”) read with Regulation 31 of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the “SEBI ICDR Regulations”). This Offer is being made through the Book Building Process in accordance with Regulation 6(2) of the SEBI ICDR Regulations wherein not less than 75% of the Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers (“QIBs”) (the “QIB Portion”), provided that our Company and the Promoter Selling Shareholder in consultation with the BRLMs may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis (“Anchor Investor Portion”). One-third of the Anchor Investor Portion shall be reserved for domestic Mutual Funds, subject to valid Bids being received from the domestic Mutual Funds at or above the Anchor Investor Allocation Price.


Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders (other than Anchor Investors), including Mutual Funds, subject to valid Bids being received at or above the Offer Price. If at least 75% of the Offer cannot be allotted to QIBs, the Bid Amounts received by our Company shall be refunded. Further, not more than 15% of the Offer shall be available for allocation on a proportionate basis to Non-Institutional Bidders and not more than 10% of the Offer shall be available for allocation to Retail Individual Bidders (“RIBs”) in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. All Bidders, other than Anchor Investors, are mandatorily required to participate in the Offer through the Application Supported by Blocked Amount (“ASBA”) process by providing details of their respective ASBA Account, which will be blocked by the Self Certified Syndicate Banks (“SCSBs”), or through the UPI Mechanism. Anchor Investors are not permitted to participate in the Anchor Investor Portion through the ASBA process.


For details, see “Offer Information” beginning on page 314 of the Red Herring Prospectus.

The Equity Shares offered through Red Herring Prospectus are proposed to be listed on BSE and NSE.

ICICI Securities Limited and Axis Capital Limited are the Book Running Lead Managers

Please also refer to the statutory advertisement attached separately with the mail.


Disclaimer:

Supriya Lifescience Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares and has filed the RHP with RoC on December 9, 2021. The RHP shall be available on the website of SEBI at www.sebi.gov.in, website of the Stock Exchanges i.e. BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, and is available on the websites of the BRLMs i.e. ICICI Securities Limited and Axis Capital Limited at www.icicisecurities.com and www.axiscapital.co.in, respectively. Bidders should note that investment in equity shares involves a high degree of risk and for details relating to the same, please see the section entitled “Risk Factors” on page 26 of the RHP. Potential Bidders should not rely on the DRHP filed with SEBI for making any investment decision.


The Equity Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the “Securities Act”) or any state securities laws in the United States, and unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable U.S. state securities laws. Accordingly, the Equity Shares are being offered and sold outside the United States in 'offshore transactions' in reliance on Regulation S and the applicable laws of each jurisdictions where such offers and sales are made. There will be no public offering in the United States.

40 views0 comments